|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4681581A
(en)
|
1983-12-05 |
1987-07-21 |
Coates Fredrica V |
Adjustable size diaper and folding method therefor
|
|
US5776093A
(en)
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
|
US5101827A
(en)
|
1985-07-05 |
1992-04-07 |
Immunomedics, Inc. |
Lymphographic and organ imaging method and kit
|
|
US4735210A
(en)
|
1985-07-05 |
1988-04-05 |
Immunomedics, Inc. |
Lymphographic and organ imaging method and kit
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5648471A
(en)
|
1987-12-03 |
1997-07-15 |
Centocor, Inc. |
One vial method for labeling antibodies with Technetium-99m
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
|
DK0486622T3
(da)
|
1989-08-09 |
1999-07-19 |
Rhomed Inc |
Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
|
|
WO1996033735A1
(en)
|
1995-04-27 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
DE19600589C1
(de)
|
1996-01-10 |
1997-01-16 |
Univ Eberhard Karls |
Antikörper A3C6E2
|
|
US6218519B1
(en)
|
1996-04-12 |
2001-04-17 |
Pro-Neuron, Inc. |
Compounds and methods for the selective treatment of cancer and bacterial infections
|
|
WO1998013059A1
(en)
|
1996-09-27 |
1998-04-02 |
Bristol-Myers Squibb Company |
Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
|
CA2722378C
(en)
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
|
WO1998025957A2
(en)
|
1996-12-13 |
1998-06-18 |
Human Genome Sciences, Inc. |
HUMAN Prt1-LIKE SUBUNIT PROTEIN (hPrt1) AND HUMAN eIF4G-LIKE PROTEIN (p97) GENES
|
|
EA003398B1
(ru)
|
1998-05-22 |
2003-04-24 |
Дайити Фармасьютикал Ко., Лтд. |
Лекарственный комплекс c полимерным носителем
|
|
US6372448B1
(en)
|
1998-12-30 |
2002-04-16 |
Millennium Pharmaceuticals, Inc. |
Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides
|
|
US6268488B1
(en)
|
1999-05-25 |
2001-07-31 |
Barbas, Iii Carlos F. |
Prodrug activation using catalytic antibodies
|
|
US20040052793A1
(en)
|
2001-02-22 |
2004-03-18 |
Carter Paul J. |
Caspase activivated prodrugs therapy
|
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
US20050180972A1
(en)
|
2002-07-31 |
2005-08-18 |
Wahl Alan F. |
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
CA2575791A1
(en)
*
|
2004-08-03 |
2006-02-16 |
Dyax Corp. |
Hk1-binding proteins
|
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
|
US8716195B2
(en)
|
2005-11-14 |
2014-05-06 |
Bioren, Inc. |
Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
|
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之ｃ-ｋｉｔ抗體
|
|
ES2371085T3
(es)
|
2006-05-27 |
2011-12-27 |
Faulstich, Heinz, Dr. |
Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
|
|
WO2008067115A2
(en)
*
|
2006-11-03 |
2008-06-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Selective immunodepletion of endogenous stem cell niche for engraftment
|
|
JP2010534469A
(ja)
|
2007-07-25 |
2010-11-11 |
アストラゼネカ アクチボラグ |
Ｋｄｒ指向性標的化結合物質およびその使用
|
|
HUE035700T2
(en)
|
2008-11-07 |
2018-05-28 |
Galaxy Biotech Llc |
Monoclonal antibodies to Fibroblast Growth Factor receptor 2
|
|
JO3096B1
(ar)
|
2008-11-07 |
2017-03-15 |
Imclone Llc |
الأجسام المضادة لمستقبل ii مضاد tgfb
|
|
ES2784829T3
(es)
|
2009-04-08 |
2020-10-01 |
Faulstich Heinz Dr |
Componentes de unión a la superficie de células terapéuticas provistos de amatoxina diseñados para terapia de tumores
|
|
KR20120128686A
(ko)
|
2010-02-18 |
2012-11-27 |
심포젠 에이/에스 |
녹농균의 혈청형 ａ 지질다당류에 대한 항체
|
|
EP2603529A1
(en)
|
2010-08-13 |
2013-06-19 |
Roche Glycart AG |
Anti-tenascin-c a2 antibodies and methods of use
|
|
ES2402254T3
(es)
|
2010-09-30 |
2013-04-30 |
Heidelberg Pharma Ag |
Conjugados de amatoxinas con ligadores mejorados
|
|
US9540443B2
(en)
*
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
EP2497499A1
(en)
|
2011-03-10 |
2012-09-12 |
Heidelberg Pharma GmbH |
Amatoxin-conjugates with improved linkages
|
|
AR086044A1
(es)
*
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
|
|
US20130280282A1
(en)
|
2012-04-24 |
2013-10-24 |
Daiichi Sankyo Co., Ltd. |
Dr5 ligand drug conjugates
|
|
EP2684865A1
(en)
|
2012-07-13 |
2014-01-15 |
Heidelberg Pharma GmbH |
Methods for synthesizing amatoxin building block and amatoxins
|
|
US20150218220A1
(en)
|
2012-09-12 |
2015-08-06 |
Brian Alan MENDELSOHN |
Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
|
|
CN115137753A
(zh)
*
|
2013-02-05 |
2022-10-04 |
细胞结构公司 |
来自胎盘的自然杀伤细胞
|
|
EP2774624A1
(en)
|
2013-03-04 |
2014-09-10 |
Heidelberg Pharma GmbH |
Amatoxin derivatives
|
|
FR3008408B1
(fr)
|
2013-07-11 |
2018-03-09 |
Mc Saf |
Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
|
|
WO2015006475A1
(en)
|
2013-07-12 |
2015-01-15 |
Biogen Idec International Neuroscience Gmbh |
Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
|
|
US10421802B2
(en)
|
2013-10-18 |
2019-09-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
|
|
JP6441949B6
(ja)
*
|
2013-11-05 |
2019-01-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ヒト中和抗ｋｉｔ抗体及びその使用
|
|
KR102442906B1
(ko)
|
2013-12-19 |
2022-09-14 |
씨젠 인크. |
표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
|
|
CN106456749B
(zh)
|
2014-03-11 |
2021-03-30 |
小利兰·斯坦福大学托管委员会 |
抗SIRPα抗体和双特异性巨噬细胞增强型抗体
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
JP6899771B2
(ja)
*
|
2014-08-12 |
2021-07-14 |
ギリース・マッキンドー・リサーチ・インスティチュートＧｉｌｌｉｅｓ Ｍｃｉｎｄｏｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ |
癌の診断及び治療
|
|
EP3215519A1
(en)
|
2014-11-06 |
2017-09-13 |
Novartis AG |
Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
|
|
EP3268047B9
(en)
|
2015-03-09 |
2024-01-10 |
Heidelberg Pharma Research GmbH |
Amatoxin-antibody conjugates
|
|
EP3273984B1
(en)
|
2015-03-25 |
2021-05-05 |
Children's Hospital Medical Center |
Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
|
|
HK1256681A1
(zh)
|
2015-04-06 |
2019-10-04 |
President And Fellows Of Harvard College |
用於非清髓性预处理的组合物和方法
|
|
SI3280441T1
(sl)
|
2015-04-07 |
2022-01-31 |
Alector Llc |
Protitelesa anti-sortilin in metoda njihove uporabe
|
|
WO2016164745A1
(en)
|
2015-04-10 |
2016-10-13 |
The Methodist Hospital System |
Cd117 ligand-drug conjugates for targeted cancer therapy
|
|
US10526413B2
(en)
|
2015-10-02 |
2020-01-07 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specific for OX40
|
|
PE20181326A1
(es)
|
2015-11-03 |
2018-08-20 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
|
KR20260018979A
(ko)
|
2016-02-05 |
2026-02-09 |
젠맵 에이/에스 |
개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
|
|
BR112018071465A2
(pt)
|
2016-04-20 |
2019-02-05 |
Hangzhou Dac Biotech Co Ltd |
derivados de toxinas de amanita e sua conjugação a uma molécula de ligação celular
|
|
WO2017191579A1
(en)
|
2016-05-05 |
2017-11-09 |
Novartis Ag |
Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
|
|
IL263744B2
(en)
|
2016-06-17 |
2023-11-01 |
Magenta Therapeutics Inc |
Compositions and methods for the depletion of cd117 plus cells
|
|
WO2018183613A1
(en)
*
|
2017-03-31 |
2018-10-04 |
The Children's Medical Center Corporation |
Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
|
|
WO2019084057A2
(en)
*
|
2017-10-24 |
2019-05-02 |
Magenta Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
|
|
WO2019084067A1
(en)
*
|
2017-10-24 |
2019-05-02 |
Magenta Therapeutics, Inc. |
ANTI-CD117 ANTIBODIES AND METHODS OF USE
|
|
KR20200069364A
(ko)
|
2017-10-24 |
2020-06-16 |
마젠타 테라퓨틱스 인코포레이티드 |
Cd117+ 세포의 고갈을 위한 조성물 및 방법
|
|
JP2021526525A
(ja)
|
2018-06-07 |
2021-10-07 |
マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
|
|
WO2020092655A1
(en)
|
2018-10-30 |
2020-05-07 |
Magenta Therapeutics, Inc. |
Methods for allogeneic hematopoietic stem cell transplantation
|
|
EP3959242A4
(en)
|
2019-04-24 |
2023-09-13 |
Magenta Therapeutics, Inc. |
ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
|
|
EP3958909A4
(en)
|
2019-04-24 |
2024-01-10 |
Magenta Therapeutics, Inc. |
ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF
|
|
JP2022530443A
(ja)
|
2019-04-24 |
2022-06-29 |
マジェンタ セラピューティクス インコーポレイテッド |
抗ｃｄ１１７抗体薬物複合体およびその使用
|
|
NZ781538A
(en)
|
2019-04-24 |
2025-12-19 |
Heidelberg Pharma Res Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
JP2022531141A
(ja)
|
2019-04-24 |
2022-07-06 |
マジェンタ セラピューティクス インコーポレイテッド |
遺伝子治療のコンディショニング方法
|